1. Home
  2. GUG vs CRVS Comparison

GUG vs CRVS Comparison

Compare GUG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Active Allocation Fund of Beneficial Interest

GUG

Guggenheim Active Allocation Fund of Beneficial Interest

HOLD

Current Price

$15.17

Market Cap

518.8M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$13.90

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GUG
CRVS
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
518.8M
1.7B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
GUG
CRVS
Price
$15.17
$13.90
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$28.20
AVG Volume (30 Days)
63.1K
1.1M
Earning Date
01-01-0001
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.90
$2.54
52 Week High
$16.50
$26.95

Technical Indicators

Market Signals
Indicator
GUG
CRVS
Relative Strength Index (RSI) 27.12 35.47
Support Level $15.11 $6.65
Resistance Level $15.76 $18.73
Average True Range (ATR) 0.18 1.03
MACD -0.08 -0.36
Stochastic Oscillator 10.10 6.97

Price Performance

Historical Comparison
GUG
CRVS

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: